Sex Differences in the Association Between Frailty and Sarcopenia in Patients With Cirrhosis. [PDF]
, 2019 ObjectivesFrailty is prevalent in patients with cirrhosis and is hypothesized to result in part from sarcopenia, but the precise contribution of sarcopenia to frailty in this population is poorly understood.MethodsIncluded were patients with cirrhosis ...
Bhanji +17 more
core +2 more sources
Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. [PDF]
, 2019 The gut microbiome, the multispecies community of microbes that exists in the gastrointestinal tract, encodes several orders of magnitude more functional genes than the human genome. It also plays a pivotal role in human health, in part due to metabolism
Lynch, Susan V +3 more
core +1 more source
RENAL INJURY AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS WITH OBESITY [PDF]
Arquivos de GastroenterologiaBackground: Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the most prevalent cause of chronic hepatic disease worldwide.
Kellyane Dias CARVALHO +3 more
doaj +1 more source
Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease? [PDF]
, 2019 Lysosomal acid lipase (LAL) plays a key role in intracellular lipid metabolism. Reduced LAL activity promotes increased multi-organ lysosomal cholesterol ester storage, as observed in two recessive autosomal genetic diseases, Wolman disease and ...
Angelico, F +7 more
core +1 more source
DIETARY FOOD FORTIFIED WITH OROTIC ACID AND LIVER FUNCTION
Makara Seri Sains, 2011 The effects of dietary food fortified with orotic acid (1.0%) on liver function were studied in rats. The rats fed withorotic acid promoted liver triglyceride content markedly, that was 5-fold higher than that of the control.
Yohanes Buang
doaj
Терапевтический архивBackground. Despite active research, drug treatment options for metabolic associated fatty liver disease (MAFLD) are limited, and there are no currently approved drugs for patients with MAFLD.
Elena V. Vinnitskaya +6 more
doaj +1 more source
Development of NASH in Obese Mice is Confounded by Adipose Tissue Increase in Inflammatory NOV and Oxidative Stress [PDF]
, 2018 Aim. Nonalcoholic steatohepatitis (NASH) is the consequence of insulin resistance, fatty acid accumulation, oxidative stress, and lipotoxicity.We hypothesize that an increase in the inflammatory adipokine NOV decreases antioxidant Heme Oxygenase 1 (HO- 1)
Abraham, Nader G. +13 more
core +1 more source
The potential of glycomics as prognostic biomarkers in liver disease and liver transplantation [PDF]
, 2019 The study of glycomics is a novel and fascinating approach for the development of biomarkers. It has become clear that in the field of liver disease specific glycomic patters are present in specific disease states, which has led to the development of ...
Callewaert, Nico +3 more
core
Journal of Research in Medical Sciences, 2017 Background: Nonalcoholic fatty liver disease (NAFLD) includes a group of chronic liver disorders caused by irregular accumulation of fat in liver tissue.
Ali Asadollahpoor +2 more
doaj +1 more source
No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial [PDF]
, 2016 Background: Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder worldwide, reaching prevalence up to 90 % in obese patients with type 2 diabetes (T2D), and representing an independent risk factor for cardiovascular mortality ...
ANGELICO, Francesco +15 more
core +2 more sources